Does the media favor FTRE or MLAB?

In the previous week, Mesa Laboratories had 1 more articles in the media than Fortrea. MarketBeat recorded 2 mentions for Mesa Laboratories and 1 mentions for Fortrea. Fortrea's average media sentiment score of 1.32 beat Mesa Laboratories' score of 0.91 indicating that Fortrea is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesa Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRVI or MLAB?

In the previous week, Maravai LifeSciences and Maravai LifeSciences both had 2 articles in the media. Mesa Laboratories' average media sentiment score of 0.91 beat Maravai LifeSciences' score of 0.31 indicating that Mesa Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesa Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLAB or BLFS?

In the previous week, BioLife Solutions had 2 more articles in the media than Mesa Laboratories. MarketBeat recorded 4 mentions for BioLife Solutions and 2 mentions for Mesa Laboratories. BioLife Solutions' average media sentiment score of 1.30 beat Mesa Laboratories' score of 0.91 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLAB or PSNL?

In the previous week, Personalis had 10 more articles in the media than Mesa Laboratories. MarketBeat recorded 12 mentions for Personalis and 2 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.91 beat Personalis' score of 0.50 indicating that Mesa Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mesa Laboratories (MLAB) Competitors

$133.01 -1.62 (-1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$133.57 +0.56 (+0.42%)

As of 07:42 PM Eastern

Compare

MLAB vs. ALMR, FTRE, MRVI, BLFS, and PSNL

Should you buy Mesa Laboratories stock or one of its competitors? Mesa Laboratories's main competitors and comparable companies include Alamar Biosciences (ALMR), Fortrea (FTRE), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), and Personalis (PSNL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Mesa Laboratories compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Mesa Laboratories (NASDAQ:MLAB) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

90.6% of Mesa Laboratories shares are held by institutional investors. 2.8% of Mesa Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mesa Laboratories has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	30.05	-$29.82M	-$1.96	N/A
Mesa Laboratories	$249.73M	2.98	$6.71M	$0.84	158.35

Alamar Biosciences currently has a consensus target price of $31.80, indicating a potential downside of 1.06%. Mesa Laboratories has a consensus target price of $110.00, indicating a potential downside of 17.30%. Given Alamar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Alamar Biosciences is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Mesa Laboratories had 2 more articles in the media than Alamar Biosciences. MarketBeat recorded 2 mentions for Mesa Laboratories and 0 mentions for Alamar Biosciences. Mesa Laboratories' average media sentiment score of 0.91 beat Alamar Biosciences' score of 0.00 indicating that Mesa Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
Alamar Biosciences	Neutral
Mesa Laboratories	Positive

Mesa Laboratories has a net margin of 1.92% compared to Alamar Biosciences' net margin of 0.00%. Mesa Laboratories' return on equity of 22.72% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Mesa Laboratories	1.92%	22.72%	9.82%

Summary

Mesa Laboratories beats Alamar Biosciences on 11 of the 15 factors compared between the two stocks.

How does Mesa Laboratories compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Mesa Laboratories has a net margin of 1.92% compared to Fortrea's net margin of -3.18%. Mesa Laboratories' return on equity of 22.72% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Mesa Laboratories	1.92%	22.72%	9.82%

Fortrea has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

90.6% of Mesa Laboratories shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Comparatively, 2.8% of Mesa Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Fortrea presently has a consensus price target of $22.00, indicating a potential upside of 12.70%. Mesa Laboratories has a consensus price target of $110.00, indicating a potential downside of 17.30%. Given Fortrea's stronger consensus rating and higher possible upside, equities analysts clearly believe Fortrea is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mesa Laboratories has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.69	-$986.20M	-$0.91	N/A
Mesa Laboratories	$249.73M	2.98	$6.71M	$0.84	158.35

In the previous week, Mesa Laboratories had 1 more articles in the media than Fortrea. MarketBeat recorded 2 mentions for Mesa Laboratories and 1 mentions for Fortrea. Fortrea's average media sentiment score of 1.32 beat Mesa Laboratories' score of 0.91 indicating that Fortrea is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesa Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mesa Laboratories beats Fortrea on 10 of the 16 factors compared between the two stocks.

How does Mesa Laboratories compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, Maravai LifeSciences and Maravai LifeSciences both had 2 articles in the media. Mesa Laboratories' average media sentiment score of 0.91 beat Maravai LifeSciences' score of 0.31 indicating that Mesa Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesa Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesa Laboratories has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	10.30	-$130.77M	-$0.52	N/A
Mesa Laboratories	$249.73M	2.98	$6.71M	$0.84	158.35

Mesa Laboratories has a net margin of 1.92% compared to Maravai LifeSciences' net margin of -37.07%. Mesa Laboratories' return on equity of 22.72% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Mesa Laboratories	1.92%	22.72%	9.82%

Maravai LifeSciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Maravai LifeSciences presently has a consensus price target of $6.83, indicating a potential downside of 7.28%. Mesa Laboratories has a consensus price target of $110.00, indicating a potential downside of 17.30%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 2.8% of Mesa Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Mesa Laboratories beats Maravai LifeSciences on 11 of the 15 factors compared between the two stocks.

How does Mesa Laboratories compare to BioLife Solutions?

Mesa Laboratories (NASDAQ:MLAB) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

90.6% of Mesa Laboratories shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 2.8% of Mesa Laboratories shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mesa Laboratories has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

Mesa Laboratories presently has a consensus target price of $110.00, suggesting a potential downside of 17.30%. BioLife Solutions has a consensus target price of $31.38, suggesting a potential downside of 16.87%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09

In the previous week, BioLife Solutions had 2 more articles in the media than Mesa Laboratories. MarketBeat recorded 4 mentions for BioLife Solutions and 2 mentions for Mesa Laboratories. BioLife Solutions' average media sentiment score of 1.30 beat Mesa Laboratories' score of 0.91 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesa Laboratories has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.73M	2.98	$6.71M	$0.84	158.35
BioLife Solutions	$96.21M	19.19	-$4.59M	$1.16	32.53

BioLife Solutions has a net margin of 53.29% compared to Mesa Laboratories' net margin of 1.92%. Mesa Laboratories' return on equity of 22.72% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
BioLife Solutions	53.29%	2.70%	2.49%

Summary

BioLife Solutions beats Mesa Laboratories on 10 of the 16 factors compared between the two stocks.

How does Mesa Laboratories compare to Personalis?

Mesa Laboratories (NASDAQ:MLAB) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

90.6% of Mesa Laboratories shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 2.8% of Mesa Laboratories shares are held by insiders. Comparatively, 4.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mesa Laboratories has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Personalis has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

Mesa Laboratories currently has a consensus price target of $110.00, indicating a potential downside of 17.30%. Personalis has a consensus price target of $14.54, indicating a potential downside of 11.10%. Given Personalis' stronger consensus rating and higher probable upside, analysts plainly believe Personalis is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Personalis had 10 more articles in the media than Mesa Laboratories. MarketBeat recorded 12 mentions for Personalis and 2 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.91 beat Personalis' score of 0.50 indicating that Mesa Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesa Laboratories has a net margin of 1.92% compared to Personalis' net margin of -153.84%. Mesa Laboratories' return on equity of 22.72% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
Personalis	-153.84%	-46.47%	-35.30%

Mesa Laboratories has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.73M	2.98	$6.71M	$0.84	158.35
Personalis	$69.65M	24.58	-$81.27M	-$1.09	N/A

Summary

Mesa Laboratories beats Personalis on 9 of the 16 factors compared between the two stocks.

Get Mesa Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLAB vs. The Competition

Export

Metric	Mesa Laboratories	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$744.32M	$10.52B	$7.21B	$13.10B
Dividend Yield	0.49%	1.45%	2.53%	13.00%
P/E Ratio	158.35	73.29	274.58	25.69
Price / Sales	2.98	108.39	648.78	85.88
Price / Cash	11.20	27.60	76.31	52.02
Price / Book	3.95	5.82	10.44	6.32
Net Income	$6.71M	$56.67B	$3.49B	$359.73M
7 Day Performance	6.16%	4.39%	0.51%	1.35%
1 Month Performance	6.61%	2.47%	-3.38%	-3.68%
1 Year Performance	89.64%	28.33%	16.04%	5.56%

Mesa Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLAB Mesa Laboratories	1.8827 of 5 stars	$133.01 -1.2%	$110.00 -17.3%	+81.9%	$744.32M	$249.73M	158.35	717
ALMR Alamar Biosciences	1.1219 of 5 stars	$28.75 +2.7%	$31.80 +10.6%	N/A	$2.00B	$100.42M	N/A	222
FTRE Fortrea	3.1614 of 5 stars	$19.73 +13.3%	$22.00 +11.5%	+111.9%	$1.88B	$2.72B	N/A	14,300	Positive News
MRVI Maravai LifeSciences	1.1907 of 5 stars	$6.88 +3.0%	$6.83 -0.7%	+171.3%	$1.79B	$208.78M	N/A	415
BLFS BioLife Solutions	2.5561 of 5 stars	$36.39 +2.7%	$31.38 -13.8%	+50.6%	$1.78B	$96.21M	31.37	155	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLAB) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesa Laboratories (MLAB) Competitors

MLAB vs. ALMR, FTRE, MRVI, BLFS, and PSNL

How does Mesa Laboratories compare to Alamar Biosciences?

Summary

How does Mesa Laboratories compare to Fortrea?

Summary

How does Mesa Laboratories compare to Maravai LifeSciences?

Summary

How does Mesa Laboratories compare to BioLife Solutions?

Summary

How does Mesa Laboratories compare to Personalis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLAB vs. The Competition

Mesa Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesa Laboratories (MLAB) Competitors

MLAB vs. ALMR, FTRE, MRVI, BLFS, and PSNL

How does Mesa Laboratories compare to Alamar Biosciences?

Do insiders & institutionals have more ownership in ALMR or MLAB?

Which has better valuation & earnings, ALMR or MLAB?

Do analysts recommend ALMR or MLAB?

Does the media favor ALMR or MLAB?

Is ALMR or MLAB more profitable?

Summary

How does Mesa Laboratories compare to Fortrea?

Is FTRE or MLAB more profitable?

Which has more volatility and risk, FTRE or MLAB?

Do insiders and institutionals have more ownership in FTRE or MLAB?

Do analysts recommend FTRE or MLAB?

Which has higher earnings and valuation, FTRE or MLAB?

Does the media favor FTRE or MLAB?

Summary

How does Mesa Laboratories compare to Maravai LifeSciences?

Does the media prefer MRVI or MLAB?

Which has stronger valuation & earnings, MRVI or MLAB?

Is MRVI or MLAB more profitable?

Which has more risk & volatility, MRVI or MLAB?

Do analysts prefer MRVI or MLAB?

Do institutionals & insiders believe in MRVI or MLAB?

Summary

How does Mesa Laboratories compare to BioLife Solutions?

Do institutionals and insiders believe in MLAB or BLFS?

Which has more volatility & risk, MLAB or BLFS?

Do analysts prefer MLAB or BLFS?

Does the media refer more to MLAB or BLFS?

Which has preferable valuation & earnings, MLAB or BLFS?

Is MLAB or BLFS more profitable?

Summary

How does Mesa Laboratories compare to Personalis?

Do insiders and institutionals have more ownership in MLAB or PSNL?

Which has more risk & volatility, MLAB or PSNL?

Do analysts recommend MLAB or PSNL?

Does the media favor MLAB or PSNL?

Is MLAB or PSNL more profitable?

Which has preferable earnings and valuation, MLAB or PSNL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLAB vs. The Competition

Mesa Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools